Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.
Phase 2
Completed
NCT03427866
| Condition | Myelofibrosis |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Massachusetts General Hospital |
|---|
| Status | Completed |
|---|
| Enrollment | 44 participants |
|---|
| Interventions | Ruxolitinib |
|---|
| Start date | Aug 28, 2018 |
|---|
| Completion date | May 1, 2024 |
|---|
| Results posted | Jul 9, 2026 |
|---|
Summary
This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.
GVHD Free and Relapse Free Survival at 1 Year
1 year · percentage of participants
| MF Patients Eligible for Transplant | 71 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.